INTRODUCTION {#s1}
============

The assessment of minimal residual disease (MRD) has currently become a necessary strategy to better address treatment intensity in acute leukemias \[[@R1]\]. The detection of MRD by RT-PCR is limited to those patients characterized by genetic markers. The latter include fusion genes derived from chromosome translocations, such as *PML-RAR*α *AML1* and *CBF-MYH11^2^* or mutations, for example nucleophosmin (*NPM1*), \[[@R1], [@R3]\] which has been validated as a sensitive marker of MRD detection. More recently, studies of next generation sequencing (NGS) allowed to enlarge the spectrum of genetic abnormalities by discovering new mutations and aberrations \[[@R4]\] Basing on these studies, other genetic markers are under investigation, including IDH1 and IDH2 mutations which occur in less than 10% of the patients \[[@R5]\].

Other genes found overexpressed in AML have been validated for MRD detection in many clinical settings. Among them, one of the most exploited is the Wilms tumor gene (*WT1*) \[[@R6]--[@R8]\].

Studies of NGS clearly showed that in AML at diagnosis there is a founding clone which prevails and several small subclones, characterized by different mutations, which are often undetectable by Sanger sequencing. These subclones can be selected by chemotherapy or by molecular targeted therapies and expand over time thus generating chemoresistance or relapse \[[@R4], [@R9]\].

Many studies suggest that *WT1*, although not associated with a specific leukemic clone, is very sensitive in the detection of the persistence or of the reappearance of the disease \[[@R8]\] The fact that its expression is not related to specific genetic alterations allows *WT1* to monitor the kinetic of the leukemic cells. Since *WT1* is not overexpressed only in AML but in other hematological malignancies including myelodysplastic syndromes \[[@R10]\] and myeloproliferative disorders, \[[@R11]\] it could be considered a "universal marker" of clonal hematopoiesis. Despite the fact that the majority of AML at diagnosis overexpresses *WT1*, in about 20-30% of AML the gene is not significantly overexpressed \[[@R8]\]. We therefore explored the possibility of additional molecular markers to monitor the disease.

The meningioma 1 gene (*MN1*), located on chromosome 22q11, was cloned from a patient affected by meningioma characterized by the translocation t(4;22) (p16;q11) \[[@R12]\]. Additional studies identified the fusion between *TEL* and *MN1* genes in AML patients with translocations t(12;22) (p13;q11) \[[@R13]\]. This genetic alteration, although very rare, represents a relevant prognostic factor with a negative impact on survival. Despite the role of this fusion transcript, it was shown that *MN1* overexpression represents a negative prognostic factor in terms of disease free survival \[[@R14]\].

Heuser and colleagues \[[@R14]\] investigated the significance of *MN1* expression in a uniformly treated cohort of adult AML patients with normal karyotype. In this study the prognostic relevance of *MN1* was compared to other prognostic factors such as *FLT3* internal tandem duplication (ITD), *MLL* and *NPM1* mutations. This study suggests that *MN1* overexpression is an independent prognostic marker in AML with normal karyotype and it is associated with shorter relapse free survival (RFS) and shorter overall survival (OS) \[[@R14]\].

The two main objects of the present study were the identification and characterization of the subset of patients showing *MN1* overexpression and the validation of *MN1* as a marker for MRD detection.

RESULTS {#s2}
=======

MN1 expression in AML patients at diagnosis {#s2_1}
-------------------------------------------

The expression levels of *MN1* transcript in normal controls and in leukemia samples at diagnosis are summarized in Table [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}. The *MN1* levels were very low in normal samples: the mean copy number of *MN1*/10^4^ *ABL* copies is 130±94 (median 136; range 9-300) in peripheral blood (PB) and 285 ±117 in BM (median 254, range 80-500).

###### *MN1* expression in normal and AML samples. BM= bone marrow, PB= peripheral blood NV= not valuable, SD= standard deviation, CTRL= healthy control

             Cytogenetic group   Type of samples   No. of samples tested   No. and percentage of patients with MN1 overexpression   *MN1 copies/10^4^ ABL copies*           
  ---------- ------------------- ----------------- ----------------------- -------------------------------------------------------- ------------------------------- ------- ------------
  **CTRL**                       BM                20                                                                               285±117                         254     80-500
                                 PB                30                                                                               130±94                          136     9-300
                                 CD34+             6                                                                                223±56                          215     149-300
             **TOTAL**                             **56**                                                                                                                   
  **AML**    normal karyotype    BM                79                      37 (47%)                                                 9766±16590                      5136    852-90230
                                 PB                19                      9 (47%)                                                  7125±4663                       6780    1367-15900
             t(15;17)            BM                25                      0 (0%)                                                   129±49                          130     25-219
                                 PB                7                       0 (0%)                                                   99±75                           95      20-250
             inv(16)             BM                16                      16 (100%)                                                44270±26285                     46950   2149-98000
                                 PB                6                       6 (100%)                                                 35200±21771                     34500   1400-67999
             t(8;21)             BM                12                      6 (50%)                                                  17848±10925                     16950   3500-34000
                                 PB                4                       4 (100%)                                                 16052±26665                     3475    1260-56000
             complex K           BM                1                       1 (100%)                                                 21080                           NV      NV
             t(9;22)             BM                1                       1(100%)                                                  9860                            NV      NV
             trysomy 9           BM                1                       1(100%)                                                  8770                            NV      NV
             5q-                 BM                1                       1(100%)                                                  45935                           NV      NV
             **TOTAL**                             **172**                                                                                                                  

###### Clinical characteristics of the patients enrolled in the study. Treatment, indicated as A, B, C and D, is described in the "materials and methods" section

  UPN   age   sex   cytogenetic   *NPM1*   *FLT3*   treatment   *MN1* copies/10000 ABL copies in BM   *WT1* copies/10000 ABL copies in BM   *NPM1* copies/10000 ABL copies
  ----- ----- ----- ------------- -------- -------- ----------- ------------------------------------- ------------------------------------- --------------------------------
  1     22    M     NK            y        N        A           199                                   156                                   10230
  2     36    M     NK            y        Y        A           15900                                 3688                                  1860
  3     66    F     NK            y        Y        B           199                                   270                                   6780
  4     70    M     NK            y        N        B           111                                   189                                   7620
  5     38    F     NK            y        N        A           145                                   340                                   NA
  6     44    F     NK            y        N        A           199                                   1560                                  11831
  7     49    F     NK            y        N        A           111                                   223                                   4210
  8     57    F     NK            y        N        A           322                                   1700                                  NA
  9     72    M     NK            y        N        B           444                                   568                                   NA
  10    61    M     NK            y        Y        C           430                                   13400                                 3280
  11    19    F     NK            y        N        A           90230                                 13200                                 8800
  12    28    M     NK            y        N        A           10240                                 3400                                  NA
  13    32    M     NK            y        Y        A           50                                    450                                   12555
  14    45    M     NK            y        N        A           3570                                  22                                    NA
  15    31    M     NK            y        Y        A           56000                                 3240                                  18340
  16    60    F     NK            y        N        A           11100                                 390                                   2102
  17    66    M     NK            y        Y        B           14637                                 12                                    NA
  18    73    F     NK            y        N        B           265                                   590                                   NA
  19    74    F     NK            y        N        B           300                                   200                                   9090
  20    29    F     NK            y        N        A           1453                                  37                                    15910
  21    18    M     NK            y        Y        A           111                                   11                                    NA
  22    26    M     NK            y        N        A           2450                                  2350                                  2230
  23    29    F     NK            y        N        A           4500                                  8090                                  NA
  24    38    F     NK            y        N        A           5080                                  9030                                  NA
  25    54    M     NK            y        N        A           344                                   88                                    13905
  26    58    M     NK            y        N        A           1460                                  9000                                  NA
  27    73    M     NK            y        N        B           2466                                  45                                    17600
  28    70    F     NK            y        N        B           8799                                  23                                    NA
  29    48    F     NK            y        N        A           666                                   1900                                  NA
  30    68    F     NK            y        Y        B           156                                   340                                   1190
  31    44    M     NK            y        N        A           468                                   1200                                  NA
  32    41    M     NK            y        N        A           2566                                  18                                    220
  33    50    F     NK            y        N        A           243                                   2510                                  NA
  34    74    M     NK            y        N        B           222                                   2560                                  NA
  35    73    F     NK            y        N        B           1890                                  40                                    80279
  36    30    M     NK            y        N        A           1570                                  62                                    NA
  37    49    F     NK            y        N        A           5555                                  5200                                  NA
  38    45    M     NK            y        N        A           400                                   250                                   7700
  39    27    M     NK            y        Y        A           345                                   660                                   NA
  40    69    F     NK            y        N        B           6870                                  66                                    NA
  41    22    F     NK            y        N        A           1790                                  21900                                 2200
  42    30    M     NK            y        N        A           5666                                  10300                                 NA
  43    68    M     NK            y        N        B           3573                                  10                                    NA
  44    65    M     NK            y        N        B           1888                                  23200                                 14200
  45    61    F     NK            y        N        A           12500                                 8700                                  NA
  46    45    M     NK            N        N        A           120                                   7800                                  
  47    31    M     NK            N        N        A           258                                   2140                                  
  48    30    F     NK            N        Y        A           340                                   220                                   
  49    48    F     NK            N        N        A           422                                   900                                   
  50    44    F     NK            N        N        A           254                                   8560                                  
  51    48    F     NK            N        N        C           18890                                 22                                    
  52    31    F     NK            N        D835     A           299                                   334                                   
  53    64    M     NK            N        N        A           154                                   14500                                 
  54    63    M     NK            N        N        C           197                                   2230                                  
  55    20    F     NK            N        N        A           15730                                 13200                                 
  56    46    M     NK            N        N        A           13000                                 78                                    
  57    66    F     NK            N        N        B           312                                   223                                   
  58    33    M     NK            N        Y        A           311                                   1880                                  
  59    47    M     NK            N        N        A           4500                                  34                                    
  60    74    F     NK            N        N        B           500                                   890                                   
  61    60    F     NK            N        N        C           211                                   228                                   
  62    61    M     NK            N        N        A           466                                   2460                                  
  63    70    M     NK            N        N        B           444                                   2184                                  
  64    22    M     NK            N        N        A           499                                   3340                                  
  65    50    M     NK            N        N        A           476                                   5510                                  
  66    49    F     NK            N        N        C           311                                   1990                                  
  67    32    F     NK            N        N        A           6780                                  28                                    
  68    72    F     NK            N        N        B           8900                                  88                                    
  69    44    F     NK            N        N        A           222                                   750                                   
  70    70    M     NK            N        D835     B           143                                   145                                   
  71    28    M     NK            N        N        A           5136                                  2200                                  
  72    36    F     NK            N        N        A           5305                                  5780                                  
  73    49    M     NK            N        N        A           852                                   31                                    
  74    51    F     NK            N        N        A           1674                                  8800                                  
  75    70    M     NK            N        N        B           1367                                  3280                                  
  76    66    M     NK            N        D835     B           1790                                  1120                                  
  77    42    F     NK            N        Y        A           200                                   676                                   
  78    26    F     NK            N        N        A           210                                   2250                                  
  79    19    F     NK            N        N        A           5680                                  34                                    
  80    56    F     t(15;17)      N        N        D           192                                   13450                                 
  81    66    F     t(15;17)      N        N        D           165                                   23410                                 
  82    34    M     t(15;17)      N        N        D           177                                   7850                                  
  83    51    M     t(15;17)      N        N        D           219                                   8400                                  
  84    58    M     t(15;17)      N        N        D           200                                   29800                                 
  85    38    M     t(15;17)      N        N        D           166                                   78400                                 
  86    44    F     t(15;17)      N        Y        D           130                                   17320                                 
  87    50    M     t(15;17)      N        N        D           167                                   54700                                 
  88    39    F     t(15;17)      N        N        D           155                                   3300                                  
  89    51    F     t(15;17)      N        N        D           150                                   7120                                  
  90    49    M     t(15;17)      N        N        D           90                                    2650                                  
  91    48    M     t(15;17)      N        Y        D           25                                    11070                                 
  92    44    F     t(15;17)      N        N        D           122                                   62190                                 
  93    55    F     t(15;17)      N        N        D           160                                   9240                                  
  94    60    F     t(15;17)      N        N        D           150                                   8840                                  
  95    44    M     t(15;17)      N        N        D           140                                   3780                                  
  96    49    F     t(15;17)      N        N        D           113                                   14200                                 
  97    52    M     t(15;17)      N        N        D           80                                    5891                                  
  98    56    F     t(15;17)      N        N        D           69                                    830                                   
  99    41    F     t(15;17)      N        N        D           47                                    41690                                 
  100   65    M     t(15;17)      N        N        D           76                                    27260                                 
  101   59    M     t(15;17)      N        N        D           98                                    16980                                 
  102   55    M     t(15;17)      N        Y        D           89                                    27120                                 
  103   45    M     t(15;17)      N        N        D           100                                   20050                                 
  104   62    F     t(15;17)      N        N        D           120                                   15380                                 
  105   49    F     t(8;21)       N        N        A           34000                                 2180                                  12500
  106   21    F     t(8;21)       N        N        A           3500                                  1650                                  6580
  107   68    F     t(8;21)       N        N        B           9900                                  880                                   2490
  108   35    M     t(8;21)       N        N        A           18000                                 1530                                  57810
  109   51    M     t(8;21)       N        N        A           25788                                 14300                                 2250
  110   66    F     t(8;21)       N        N        B           15900                                 4300                                  1570
  111   32    M     t(8;21)       N        N        A           400                                   910                                   22500
  112   56    F     t(8;21)       N        N        A           340                                   22800                                 4780
  113   41    M     t(8;21)       N        Y        A           290                                   18300                                 7630
  114   34    M     t(8;21)       N        N        A           350                                   5600                                  10300
  115   48    M     t(8;21)       N        N        A           280                                   3490                                  8700
  116   68    F     t(8;21)       N        N        B           380                                   19200                                 22800
  117   29    F     inv(16)       N        N        A           21935                                 750                                   21192
  118   59    M     inv(16)       N        N        A           24128                                 3190                                  9027
  119   41    F     inv(16)       N        N        A           72022                                 1840                                  13580
  120   42    F     inv(16)       N        N        A           98000                                 2600                                  8920
  121   49    F     inv(16)       N        N        A           50900                                 2530                                  6510
  122   22    M     inv(16)       N        N        A           59000                                 4160                                  62800
  123   46    F     inv(16)       N        N        A           70280                                 3140                                  11519
  124   51    M     inv(16)       N        N        A           68900                                 1020                                  37911
  125   69    M     inv(16)       N        N        B           28000                                 1010                                  80134
  126   39    M     inv(16)       N        N        A           45000                                 47620                                 10100
  127   29    F     inv(16)       N        N        A           27900                                 5610                                  10180
  128   60    F     inv(16)       N        N        A           4700                                  5990                                  12816
  129   66    F     inv(16)       N        N        B           29804                                 6230                                  11280
  130   61    M     inv(16)       N        N        A           56700                                 980                                   29880
  131   46    F     inv(16)       N        N        A           48900                                 4700                                  10065
  132   48    M     inv(16)       N        N        A           2149                                  390                                   NA
  133   30    F     complex K     N        N        C           21080                                 36880                                 
  134   47    M     t(9;22)       N        N        A           9860                                  21370                                 
  135   60    M     46XY;+9       N        N        C           8770                                  28600                                 
  136   21    F     46XX;-5q      N        N        A           45935                                 990                                   
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Similarly, low levels of expression were detected in normal CD34+ cells obtained from healthy volunteers: mean *MN1* copies/10^4^ *ABL* copies 223±56 (median 215 copies/10^4^ *ABL* copies, range 149-300).

Conversely, as shown in Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, 47% of the samples collected at diagnosis from AML patients characterized by a normal karyotype showed abnormal expression of the *MN1* gene. In this subset of patients, the mean value of expression evaluated for 37 out of 79 BM samples showed a transcript amount above the upper limit of normal controls is 9707±16590 copies/10^4^ *ABL* copies (median 5136, range 852-90230). Interestingly, as shown in Figure [1](#F1){ref-type="fig"}, NK AML and CBF AML seem to segregate in two groups, one with normal values (below 500 *MN1* copies/10^4^ ABL copies for BM and 300 *MN1* copies for PB), the second with *MN1* values above 1000 copies. This raises the possibility of a "gray zone" between positivity and negativity. At present we cannot establish the prognostic significance of *MN1* with values falling in that range.

In accordance, 9 out of 19 PB samples presented abnormal expression with a mean value of 7125 ± 4663 (median 6780, range 1367-15900). All samples carrying the fusion transcript *CBβ-MYH11* expressed a significantly higher amount of *MN1* transcript. The mean copy number is 44270±26285 (median 46950, range 2149-98000) in BM and 35200±21771 (median 34500, range 1400-67999) in PB. These values are significantly higher as compared to controls (p\<0.0001 in both BM and PB). Fifty % of the samples characterized by the fusion gene *RUNX1-AML1* abnormally expressed *MN1.* The mean value of *MN1* copies calculated for BM cells with *MN1* expression above the upper limit established by normal samples was 17848±10925 (median 16950, range 3500-34000). All four PB samples tested presented high *MN1* values with a mean copy number of 16052±26665 (median 3475, range 1260-56000). Additionally, four AML patients with sporadic abnormalities such a t(9;22), trisomy 9, 5q-, and complex karyotype were included. All expressed abnormal *MN1* transcript values (data shown in Table [1](#T1){ref-type="table"}). Finally, the Acute Promyelocytic Leukaemia (APL) samples expressed *MN1* values comparable to those of healthy subjects in both BM (p= 0.4) and PB (p=0.08).

Interestingly, the paired analysis of 47 PB and BM samples collected from the same cohort of patients allowed us to establish a remarkable correlation between *MN1* expression in PB and BM. Regression analysis provided an r value of 0.91 (Figure [2](#F2){ref-type="fig"}).
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Stratification of patients according to the presence of *FLT3* mutation or internal tandem duplication (ITD) demonstrated no significant association between the two abnormalities. *MN1* was overexpressed in 35% of patients with *FLT3* ITD, 33% of patients with the D835 mutation and 50% of those with wild type *FTL3*.

Finally, in contrast to previously published data, we were unable to find any significant correlation between *EVI-1* and *MN1* expression (r= 0.06) or between *MN1* and *NPM1* mutation (r=0.2).

MN1 as a target for MRD detection {#s2_2}
---------------------------------

To assess the significance of *MN1* expression as a marker for MRD detection in AML, the *MN1* transcript amount was quantified during follow-up in 20 AML patients characterized by the presence of specific fusion-gene transcripts (15 *CBFβ*-*MYH11* and 5 *RUNX1-AML1*), in 8 patients with NPM1 mutation and in and 13 AML patients (including 3 resistant cases) lacking additional molecular markers but monitored by making use of *WT1* quantitative assessment, which we have previously demonstrated to strictly parallel fusion gene transcript behavior \[[@R6]\]. In all cases characterized by the presence of a fusion-gene transcript, the longitudinal pattern of *MN1* expression was always found to parallel that of the fusion gene. (Table [3](#T3){ref-type="table"}) Three representative AML cases are illustrated in Figure [3](#F3){ref-type="fig"}. In the inv(16) AML subgroup, the patient who remained in continuous complete remission (CCR) constantly showed *MN1* values within the normal range (Table [3](#T3){ref-type="table"}), whereas the five patients who ultimately relapsed showed a progressive raising of *MN1* levels above the normal range during hematological remission (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). In the cases illustrated in Figure [3](#F3){ref-type="fig"} panel A and C, *MN1* values were found above the normal range in concomitance with quite stable values of *CBFβ-MYH11* transcript in BM samples taken 3 and 4 months, respectively, before hematological relapse while the patients were still in hematological remission.

###### Simultaneous evaluation of the expression of *MN1* and fusion gene transcript (*CBF-MYH11* or *RUNX1-AML1)* or *NMP1* mutation during follow up in patients with AML

  ------------------ ------------------ --------------- -------------------- ----------------------------- ---------------------------------- --------------- -------------
  **Pt**             **Target gene**    **Diagnosis**   **Post Induction**   **CR Post consolidation I**   **CR pst Post consolidation II**   **follow-up**   **Relapse**
  1                  MN1                21935           210                  190                           192                                                
                     CBF-MYH11          21192           167                  12                            12                                                 
  2                  MN1                24128           87                   90                            100                                                
                     CBF-MYH11          9027            18                   9                             11                                                 
  3                  MN1                72022           312                  290                           97                                                 
                     CBF-MYH11          13580           212                  21                            8                                                  
  4                  MN1                98000           95                   88                            90                                                 
                     CBF-MYH11          8920            15                   21                            12                                                 
  5                  MN1                50900           320                  190                           261                                190             
                     CBF-MYH11          6510            134                  67                            52                                 30              
  6                  MN1                59000           110                  80                            90                                                 
                     CBF-MYH11          62800           180                  200                           80                                                 
  7                  MN1                70280           88                   113                           180                                883             3714
                     CBF-MYH11          11519           340                  391                           120                                312             19711
  8                  MN1                68900           37                   41                            22                                                 
                     CBF-MYH11          37911           412                  91                            11                                                 
  9                  MN1                28000           512                  193                           114                                121             
                     CBF-MYH11          80134           670                  120                           69                                 21              
  10                 MN1                45000           820                  632                           880                                920             53490
                     CBF-MYH11          10100           8                    4                             1                                  3               9980
  11                 MN1                27900           91                   102                           100                                920             10142
                     CBF-MYH11          10180           8                    6                             1                                  5               10090
  12                 MN1                4700            66                   61                            45                                                 
                     CBF-MYH11          12816           34                   12                            4                                                  
  13                 MN1                29804           97                   112                           118                                121             32560
                     CBF-MYH11          11280           8                    4                             1                                  4               10120
  14                 MN1                56700           180                  134                           153                                                
                     CBF-MYH11          29880           12                   15                            12                                                 
  15                 MN1                48900           812                  410                           880                                970             10103
                     CBF-MYH11          10065           8                    6                             1                                  3               10012
  **Pt**             **Target gene**    **Diagnosis**   **Post Induction**   **CR Post consolidation I**   **CR pst Post consolidation II**   **follow-up**   **Relapse**
  16                 MN1                34000           211                  170                           145                                161             
                     RUNX1-AML1         97170           4720                 266                           27                                 64              
  17                 MN1                3500            118                  111                           131                                880             18670
                     RUNX1-AML1         9027            19                   7                             5                                  12              8650
  18                 MN1                9900            407                  112                           109                                                
                     RUNX1-AML1         11830           229                  15                            2                                                  
  19                 MN1                18000           110                  141                           390                                1020            28910
                     RUNX1-AML1         9902            51                   4                             3                                  13              12500
  20                 MN1                25788           99                   81                            17                                                 
                     RUNX1-AML1         2250            22                   12                            8                                                  
  **Pt**             **Target gene**    **Diagnosis**   **Post Induction**   **CR Post consolidation I**   **CR pst Post consolidation II**   **follow-up**   **Relapse**
  21                 MN1                15900           113                  103                           190                                1020            24500
                     NPM1               1860            21                   11                            6                                  54              2830
  22                 MN1                90230           90                   81                            52                                                 
                     NPM1               8800            21                   2                             1                                                  
  23                 MN1                56000           2200                 860                           920                                4290            82104
                     NPM1               18340           25                   28                            31                                 72              11454
  24                 MN1                1453            105                  99                            92                                                 
                     NPM1               15910           320                  76                            34                                                 
  25                 MN1                2466            990                  800                           720                                1660            6792
                     NPM1               17600           120                  80                            31                                 60              6505
  26                 MN1                2566            62                   71                            34                                                 
                     NPM1               220             12                   2                             0                                                  
  27                 MN1                1890            63                   61                            12                                                 
                     NPM1               80279           12                   1                             1                                                  
  28                 MN1                1790            41                   44                            13                                                 
                     NPM1               2200            5                    0                             0                                                  
  **Resistant pt**   **Target genes**   **Diagnosis**   **Post Induction**                                                                                    
  29                 MN1                38910           25200                                                                                                 
                     WT1                8450            9240                                                                                                  
  30                 MN1                82100           72120                                                                                                 
                     WT1                7220            6123                                                                                                  
  31                 MN1                42193           63408                                                                                                 
                     WT1                9920            13450                                                                                                 
  ------------------ ------------------ --------------- -------------------- ----------------------------- ---------------------------------- --------------- -------------

![**Panel A and B:** *MN1* transcript expressed as number of copies/10^4^ *ABL* copies (blue line) and *CBFβ-MYH11* transcript expressed as copy number/10^4^ *ABL* copies (red line) at diagnosis and during follow-up in two patients with inv(16) who relapsed. *MN1* increased above the upper normal limit three months before relapse in patient represented in panel A. **Panel C**: *MN1* transcript (blue line), *CBFβ-MYH11*transcript (red line) and *WT1* transcript (pink line) at diagnosis and during follow-up of a patient with an inv(16) alteration who relapsed after two cycles of chemotherapy and allogeneic bone marrow transplantation (allo BMT). *MN1* and *WT1* increased above the upper normal limit four months before haematological relapse. PI= post induction, PC= post consolidation, CR= complete remission.](oncotarget-07-74082-g003){#F3}

Similarly, in the t(8;21) group, three patients who were in CCR never showed levels of *MN1* transcript above the normal range (Table [3](#T3){ref-type="table"}), whereas in the two patients who relapsed, increased *MN1 l*evels were detectable 1 and 2 months respectively before the evidence of relapse.

In addition in 8 patients with *NPM1* mutation the quantitative analysis of *MN1* and *NPM1* shows a concordance between the two markers with a progressive increase of both before relapse and normal values of *MN1* and negative *NPM1* during remission.

Finally, all patients were also monitored using *WT1* quantitative assessment. As shown in Figure [3](#F3){ref-type="fig"} panel C, and as already demonstrated in our previous study and in many studies from the literature, \[[@R15]\] *WT1* strictly paralleled the behaviour of the fusion transcripts. Furthermore, we found that *MN1* strictly paralleled *WT1* in patients without any fusion gene (Figure [4](#F4){ref-type="fig"}) and in patients with rearrangements in the core binding factor (Figure [3C](#F3){ref-type="fig"}). Figure [4](#F4){ref-type="fig"} shows the two molecular markers used during follow up of a patient who obtained a remission after two courses of chemotherapy and allogeneic bone marrow transplant. In this patient, both markers, *WT1* and *MN1*, returned to normal range and both increased three months before relapse.

![MN1 transcript (blue line) and WT1 transcript (pink line) expressed as number of copies/104 ABL copies at diagnosis and during follow-up of a patient with normal karyotype who obtained remission after chemotherapy and allogeneic bone marrow transplant and relapsed six months after transplant\
In this patient, both markers, *WT1* and *MN1*, returned to normal range and increased three months before relapse.](oncotarget-07-74082-g004){#F4}

Although the presented examples show a good degree of concordance in the curves representing *MN1* and fusion genes, they are not completely parallel. In some cases it seems that *MN1* expression, similarly to *WT1*, is cleared more rapidly than fusion gene transcripts during induction of remission, but it also seems that its elevation is more indicative than the fusion gene transcript in predicting relapse (see Figure [3](#F3){ref-type="fig"} panel A and C). At the moment this cannot be easily explained due to our lack of knowledge about the kinetics of *MN1* expression in AML.

DISCUSSION {#s3}
==========

The negative impact of the persistence of minimal residual disease after chemotherapy or before bone marrow transplantation in acute myeloid leukemia patients is well established \[[@R1]\]. RT-PCR is among the most sensitive methods used for the quantification of the MRD but it requires the presence of genetic markers in the leukemic clone including fusion transcripts or mutations \[[@R2], [@R3]\].

The disease monitoring became even more cumbersome with the genomic characterization of AML which elegantly demonstrated that, al least at onset, the acute leukemia is mainly constituted by a founding clone with a variable number of mutations and by additional subclones, nearly undetectable, carrying mutations different from the founding clone \[[@R4], [@R9]\].

These subclones might eventually be selected during chemotherapy and expand during the course of the disease \[[@R4], [@R9]\]. Considering the dynamic of the leukemic clones it should not be unpopular to suggest the use of a marker not specifically related to a clone but able to identify the presence of leukemic cells independently from their genetic lesions and their phenotype.

In addition, we must consider that in many laboratories NGS technology is not yet available and RQ-PCR targeting all the identified mutations is time consuming and expensive. The advantage of using a single "universal marker" with high sensitivity and specificity allow to better monitor the disease during therapy and in the remission phase.

Interestingly, the association of *MN1* with myeloid malignancy goes beyond *MN1* involvement in rare translocations such as t(12;22), as the gene is overexpressed in a significant percentage of AML patients. These has been already demonstrated in literature in some patients characterized by overexpression of the transcription factor ectropic viral integration 1 site (*EVI1*) \[[@R16]\] and in some adult AML patients without karyotypic abnormalities. In the latter case, overexpression of *MN1* was associated with a worse prognosis and shorter survival rate \[[@R14]\]. Despite the possibility that *MN1* could represent an independent prognostic factor for AML patients, particularly for those with a normal karyotype, there are few data regarding the expression of *MN1* in normal hematopoietic cells and in different subtypes of AML. Furthermore, there is currently no evidence that *MN1* could represent a suitable marker for minimal residual disease detection. Using a real time quantitative PCR approach, we show that *MN1* expression is detectable in all normal bone marrow and peripheral blood samples and CD34 positive cells collected from healthy subjects, although we were able to estimate that normal subjects expressed very low *MN1* levels. In contrast, a significant number of patients are characterized by high *MN1* transcript amount and, in several cases, the expression is at least 2 or 3 logs higher than controls. It appears that overexpression of *MN1* is mainly associated with the inv16 chromosomal abnormality and with a normal karyotype, whereas in t(15;17) APL the values are consistently comparable to controls. In contrast, we were unable to find any significant correlation between *FLT3* ITD or mutation or *EVI-1* overexpression. Moreover, the finding that CD34-positive cells express low levels of *MN1* transcript supports the notion that increased levels of *MN1* expression are indeed specific of leukemic blasts and not a simple consequence of the degree of differentiation. Since a significant percentage of AML shows consistently increased *MN1* expression levels, this could represent a candidate marker suitable to discriminate between normal and leukemic hematopoiesis and useful to establish the presence, persistence or reappearance of leukemic clone. In particular, our data show that 45% of AML cases lacking other molecular markers suitable for MRD monitoring express at diagnosis *MN1* transcript values above the normal range established by healthy subjects. In this subset of patients, *MN1* may represent a reliable marker for MRD detection. So far no data are available concerning the clinical significance of detection of *MN1* expression by RT-PCR for monitoring patients with acute leukemia during follow-up. The data presented in this paper show that an accurate quantitative assessment of *MN1* transcript amount allows to clearly distinguish between normal and abnormal expression levels of *MN1* and, as for *WT1*, can overcome the problem represented by the minimal amount of gene expression found in normal hematopoietic progenitors. The simultaneous quantitative assessment of the *MN1* transcript and of the specific fusion gene or *NPM1* mutation showed a good parallelism between the behaviour of the two markers. Indeed, minor discrepancies at low levels of expression of the two markers were observed. In particular, the decrease in *MN1* expression seems to be particularly rapid compared to the fusion gene transcript during the induction of remission and its elevation before relapse is more rapid and therefore it is probably more sensitive in predicting relapse. Therefore, even though the degree of sensitivity for MRD detection by analysis of *MN1* expression remains to be established, the results obtained show that an increase in *MN1* expression above normal levels can be of prognostic significance in predicting relapse during follow-up of AML patients. Although the *MN1* gene requires validation as a marker for minimal residual disease in future prospective studies, it seems to be a promising marker for this purpose and further studies should be encouraged.

MATERIALS AND METHODS {#s4}
=====================

After informed consent, 136 acute myeloid leukaemia patients and 50 healthy volunteers were included in the study. 136 bone marrow samples (BM) and 36 paired peripheral blood samples (PB) were collected from 136 AML patients at diagnosis. In addition, 41 patients were studied during follow-up. The median age was 48 years (range 18-74). All cases were classified according to FAB criteria, characterized at the cytogenetic level by conventional karyotyping and screened by RT-PCR for the presence of the most frequent fusion transcripts, as previously described.^2^ *NPM1* mutations ^3^ and *FLT3* ITD or D835 mutations were screened. *WT1* quantitative assessment is available for all samples included in the study and, furthermore, in 40 out of 136 BM samples *EVI-1* quantitative assessment was also performed. The FAB distribution was as follows: FAB M0=21, FAB M1= 22, FAB M2=26, FAB M3= 25, FAB M4= 24, FAB M5=16, FAB M6=2. Patients younger than 60 years were treated following standard protocols established by the GIMEMA Cooperative Group for the treatment of adult patients with acute myeloid leukemia which included: Induction treatment with a 3-drug regimen: Daunorubicine (DNR) 50 mg/sqm/day on days 1, 3 and 5; Cytosine-Arabinoside (ARA-C) 100 mg/sqm/day on days 1 to 10; Etoposide 100 mg/sqm/day on days 1 to 5; to be repeated in case of partial remission (PR). Consolidation therapy with DNR 50 mg/sqm/day on days 4 to 6 and intermediate-doses ARA-C (500 mg/sqm/12 h on days 1 to 6) for patients achieving complete remission (CR) after either the first or the second induction cycle.

Additional consolidation treatments with high dose ARA-C were used followed, in high risk patients by allogeneic stem cell transplantation. (This regimen is indicated as treatment A in Table [2](#T2){ref-type="table"}) Elderly or unfit patients were treated with two cycles of daunorubicin 45 mg/sqm/day on days 1, 3 plus ARA-C 100 mg/sqm/day on days 1 to 7 followed, in same cases, by autologous stem cell transplantation. (This regimen is indicated as treatment B in Table [2](#T2){ref-type="table"})

Refractory or secondary AML were treated following the Mito-FLAG scheme (Fludarabine 30 mg/sqm day 1-5, ARA-C 2000 mg/sqm day 1-5, mitoxantrone 7 mg/sqm day 1,3,5 and G-CSF 5 μg/kg from day −1) and consolidated as described above. (This regimen is indicated as treatment C in Table [2](#T2){ref-type="table"}). Finally Acute promyelocytic leukemia were treated with anthracycline-based risk-adapted chemotherapy plus all-trans retinoic acid (ATRA) \[[@R17]\]. (This regimen is indicated as treatment D in Table [2](#T2){ref-type="table"})

Complete remission was defined according to standard criteria. Finally 30 PB and 20 BM and 6 CD34+ enriched peripheral blood stem cell samples collected from healthy volunteers were included as normal control.

Real time quantitative RT-PCR (RQ-PCR) analysis of MN1 and WT1 {#s4_1}
--------------------------------------------------------------

Total RNA was extracted using TRI Reagent solution (Ambion, Waltham, MA USA). Mononuclear cells were separated on a Ficoll--Hypaque density gradient. Total RNA was extracted by standard procedure. The RT (reverse transcription) step was performed as previously described \[[@R2], [@R8]\]. RQ-PCR reactions and fluorescence measurements were made on the ABI PRISM 7700 Sequence Detection System (PE Applied Byosystems, Foster City, USA).

Briefly, the RQ-PCR primers and probe for *MN1* detection were provided by ELItech, Turin, Italy

Primers and probe for *MN1* detection are:

5′ AGAAGGCCAAACCCCAGAACC-3′

5′ GATGGTGAGGCCTTGTTTGCA-3′

5′ Fam-ACAGCAAAGAAGCCCAC-MGBNFQ 3′

For *WT1* we followed the ELN standardized method reported \[[@R8]\].

The analysis was performed in triplicate and results showing a discrepancy \>1 Ct in one of the wells were excluded and repeated. For quantitative assessment of *MN1* a calibration curve with a plasmid containing *MN1* target sequences was used (ELItech, Turin, Italy). The *MN1* values obtained by RQ-PCR were normalized with respect to the number of *ABL* transcripts and expressed as *MN1* copy number every 10^4^ copies of *ABL*. Quantitative assessment of *CBF*-*MYH11* and *RUNX1-AML1* transcripts was determined using primers and probes according to standardized procedures.^2^

Real time quantitative RT-PCR (RQ-PCR) analysis of EVI-1 {#s4_2}
--------------------------------------------------------

For *EVI-1* and *ABL* quantification, specific assays on demand kits of primers and probe (assay ID for *EVI-1* HS01118675_m1 and for ABL Hs00245445_m1 (Applied Byosystems, Foster City, USA) were used following the manufacturer\'s instructions.

All sample analysis was performed in triplicate and results showing a discrepancy \>1 Ct in one of the wells were excluded and repeated.

*EVI-1* Ct obtained by RQ-PCR was normalized with respect to the Ct of *ABL* and calibrated with universal RNA (Stratagene, Santa Clara, California, USA) and finally expressed as 2^−ΔΔCt^.

CD34-positive cells enrichment {#s4_3}
------------------------------

CD34+ cells were enriched according to a magnetic cell sorting methodology (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, mononuclear cells were labeled with a haptenized CD34 antibody (QBEND\\10) that was magnetically labelled in a second step reaction with an anti-hapten antibody coupled to super paramagnetic microbeads. Labelled cells were then separated using a high gradient magnetic separator column placed in a strong magnetic field. The magnetically stained cells were retained in the column, and when the latter was removed from the magnetic field, CD34-positive cells were eluted. At the end of the procedure, CD34 positive cells represented more that 90% of the total as determined by flow cytometric analysis.

Statistical analysis {#s4_4}
--------------------

*MN1* values obtained for different types of leukemia were compared using the Student\'s *t*-test.
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